AMPA Health ONE-D · Now Available in Menlo Park

Depression treatment
completed in one day

Dr. Earth Hasassri offers the AMPA Health ONE-D protocol, a peer-reviewed, single-day TMS regimen delivering 20 iTBS sessions in 9.5 hours, with neuroplasticity-enhancing medication. No weeks of daily clinic visits. One day. Lasting results.

87%
Response rate at 6 weeks
72%
Remission rate at 6 weeks
1
Day of treatment
1
Day
iTBS
iTBS
iTBS
iTBS
iTBS
iTBS
iTBS
iTBS
iTBS
iTBS
iTBS
iTBS
iTBS
iTBS
iTBS
iTBS
iTBS
iTBS
iTBS
iTBS
20 iTBS sessions · Every 30 minutes · 9.5 hours total
7 AM · Arrival12 PM · Midday5:30 PM · Done
The Science

How TMS works

If you've tried antidepressants and they haven't worked, TMS offers something fundamentally different: it works directly on the brain circuits that depression disrupts, using focused magnetic pulses. No surgery, no anesthesia, nothing systemic. Just targeted stimulation of the region where depression lives.

01
Magnetic coil placed on scalp
A small coil is gently placed against your scalp. That's it. No needles, no incisions, no anesthesia. It's positioned over the area of the brain responsible for mood regulation, which is consistently underactive in people with depression.
02
Magnetic pulse activates neurons
Each pulse passes painlessly through the skull and activates the neurons just beneath, essentially waking up the brain circuitry that depression has quieted. Patients typically feel a gentle tapping sensation on the scalp. Nothing more.
BEFORE ~ AFTER 20 × iTBS builds LTP
03
Repeated stimulation builds new connections
Each session builds on the last. With repeated stimulation, the brain's mood circuits grow stronger and more active, the same way a muscle responds to exercise. This is why the improvement is lasting rather than temporary.
Left DLPFC: reactivated
04
Brain circuits reactivate, mood lifts
As the brain's mood circuits reactivate and strengthen, symptoms begin to lift. Don't expect an overnight change — most patients notice meaningful improvement within 2–4 weeks as the changes settle in. The treatment is done in a day; the healing unfolds over weeks.
Targeted
Focused on the exact brain region implicated in depression
Non-invasive
No surgery, no anesthesia, no systemic side effects
Neuroplastic
Triggers lasting changes in how brain circuits function
FDA-cleared
Cleared for treatment-resistant depression since 2008
The Science

What makes ONE-D different

Traditional TMS requires patients to return to the clinic 5 days a week for 4–6 weeks, which is a significant barrier for people with busy schedules, mobility challenges, or limited access to specialty care.

The AMPA Health ONE-D protocol delivers a full course of TMS in a single day, combining an accelerated stimulation schedule with medications that help the brain respond more deeply to treatment. Published in Transcranial Magnetic Stimulation (Vaughn et al., 2025), the results outperform conventional multi-week TMS — in a fraction of the time.

Vaughn DA, Marino B, Engelbertson A, et al. "Real-world effectiveness of a single-day regimen for transcranial magnetic stimulation using Optimized, Neuroplasticity-Enhanced techniques in Depression (ONE-D): An open-label case series." Transcranial Magnetic Stimulation. November 2025. doi:10.1016/j.transm.2025.100200
Core Technology
Intermittent Theta-Burst Stimulation (iTBS)
Each of the 20 sessions delivers 600 magnetic pulses using iTBS, a compressed and highly effective form of TMS, targeting the left dorsolateral prefrontal cortex (DLPFC), the key brain circuit implicated in depression. "Theta-burst" refers to the pattern of pulse delivery: rapid bursts of three pulses fired at the brain's natural theta frequency (5 Hz), mimicking the rhythms the brain itself uses to strengthen synaptic connections. This biologically-informed pattern achieves the same therapeutic effect as traditional rTMS in a fraction of the time.
iTBS (ONE-D)
3 min
Traditional rTMS
37 min
Same 600 pulses. Same clinical efficacy. 12× faster per session.
600 pulses · 3 min per session
Accelerated Schedule
20 sessions in a single 9.5-hour day
Sessions are spaced 30 minutes apart throughout the day. Between sessions you relax in the waiting room — the spacing is deliberate, giving each session time to take effect before the next begins. What used to take weeks is finished in a day.
30-min inter-session interval
Pharmacological Enhancement
Neuroplasticity-priming medications
ONE-D pairs TMS with two medications taken as a single dose one hour before treatment begins. They help your brain respond more deeply to each session, making the effects stronger and longer-lasting.
Off-label · Physician-prescribed · Single dose
Treatment Day

What your ONE-D day looks like

Your entire TMS course is completed in one day. You arrive in the morning, receive all 20 sessions in a comfortable setting, and leave the same evening with your treatment complete.

Your ONE-D Treatment Day
Single day · 7:00 AM to 5:45 PM
7:00
D-Cycloserine 125 mg + Lisdexamfetamine 20 mg
7:15
Motor Threshold Determination
7:30
Baseline Scales: PHQ-9, GAD-7, BDI-II, and others
8:00
TMS Session: Left DLPFC, iTBS 600
1 / 20
8:30
TMS Session: Left DLPFC, iTBS 600
2 / 20
9:00
TMS Session: Left DLPFC, iTBS 600
3 / 20
9:30
TMS Session: Left DLPFC, iTBS 600
4 / 20
10:00
TMS Session: Left DLPFC, iTBS 600
5 / 20
10:30
TMS Session: Left DLPFC, iTBS 600
6 / 20
11:00
TMS Session: Left DLPFC, iTBS 600
7 / 20
11:30
TMS Session: Left DLPFC, iTBS 600
8 / 20
12:00
TMS Session: Left DLPFC, iTBS 600
9 / 20
12:30
TMS Session: Left DLPFC, iTBS 600
10 / 20
1:00
TMS Session: Left DLPFC, iTBS 600
11 / 20
1:30
TMS Session: Left DLPFC, iTBS 600
12 / 20
2:00
TMS Session: Left DLPFC, iTBS 600
13 / 20
2:30
TMS Session: Left DLPFC, iTBS 600
14 / 20
3:00
TMS Session: Left DLPFC, iTBS 600
15 / 20
3:30
TMS Session: Left DLPFC, iTBS 600
16 / 20
4:00
TMS Session: Left DLPFC, iTBS 600
17 / 20
4:30
TMS Session: Left DLPFC, iTBS 600
18 / 20
5:00
TMS Session: Left DLPFC, iTBS 600
19 / 20
5:30
Final TMS Session: Treatment Complete
20 / 20
5:45
Debrief, outcome review & head home
AM
Morning · Arrival
Preparation & medications
You arrive and meet with Dr. Hasassri. One hour before your first TMS session, you take a single oral dose of d-cycloserine and lisdexamfetamine to prime your brain's neuroplasticity for the day ahead.
Motor Threshold Confirmed
20×
All Day · 9.5 Hours
20 iTBS sessions, every 30 minutes
Every 30 minutes you receive a 3-minute iTBS session (600 pulses) to the left DLPFC. Between sessions you relax in the waiting room: read, browse, listen to music, or simply unwind. WiFi and refreshments are provided throughout the day, and lunch is included at midday.
Non-invasive · No sedation needed
PM
Evening · Completion
Debrief & head home
After your 20th session, Dr. Hasassri reviews your experience and answers questions. You leave the same evening. Your treatment is complete. Follow-up outcome monitoring is scheduled at 1, 6, and 12 weeks.
Treatment Complete
Neuroplasticity augmentation medications
Before your first session, you take two physician-prescribed medications in a single oral dose. These aren't sedatives or mood drugs — they're taken specifically to help your brain get more out of each TMS session. Research shows that depression can blunt the brain's ability to respond to stimulation. These medications counteract that, essentially preparing the brain to change.
D-cycloserine helps the brain form stronger, more durable responses to each TMS session. A rigorous 2022 clinical trial in JAMA Psychiatry found that patients who received TMS with d-cycloserine had more than double the response rate of those who received TMS alone: 73.9% versus 29.2%. Remission rates were nearly ten times higher. It is taken approximately one hour before treatment so it's active in the brain during stimulation. No serious side effects were observed.
Lisdexamfetamine supports the brain's ability to respond and adapt during treatment, helping each session have a stronger and more lasting effect.
D-cycloserineLisdexamfetamine

Both medications are used off-label as part of the ONE-D protocol and are not FDA-approved for this indication. Dr. Hasassri conducts a comprehensive medical and psychiatric evaluation to confirm safety and appropriateness before prescribing. Source: Cole J, et al. Efficacy of Adjunctive D-Cycloserine to Intermittent Theta-Burst Stimulation for Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79(12):1153–1161. doi:10.1001/jamapsychiatry.2022.3255

Published Results

What patients
actually experience

These are real outcomes from real patients: adults who had already tried medications and still weren't well. The results are tracked at 6, 12, and 26 weeks after a single treatment day. Not estimates. Not projections. Measured outcomes.

87.5%
Response rate at 6 weeks
HDRS-17
71.2%
Remission rate at 6 weeks
HDRS-17
90.6%
Response rate at 6 weeks
BDI-II
50%
Sustained remission at 26 weeks
HDRS-17 & BDI-II
Depression Symptom Score Over Time
Relief unfolds over weeks: your brain keeps healing after treatment day
You come in for one day. But the neuroplastic changes triggered by ONE-D continue unfolding for weeks. Scores keep falling, and most patients cross into remission territory by week 4 and stay there through week 12.
10 Remission
Average depression score Remission threshold (score ≤ 10) ONE-D treatment day
Source: Vaughn DA, Marino B, Engelbertson A, Dojnov A, Weiss N, Vila-Rodriguez F, et al. Real-world effectiveness of a single-day regimen for transcranial magnetic stimulation using Optimized, Neuroplasticity-Enhanced techniques in Depression (ONE-D): An open-label case series. Transcranial Magnetic Stimulation. 2025. doi:10.1016/j.transm.2025.100200. n=32 medication-resistant adults; unblinded retrospective case series; RCT data pending.
How ONE-D Stacks Up

Comparing treatment
options for depression

Depression has many treatment paths. The chart below shows how ONE-D compares to standard options, based on published clinical data. Response means a significant reduction in symptoms; remission means near or full recovery.

Response rate (≥50% symptom reduction)
Remission rate (near symptom-free)
1st Medication Trial
SSRI/SNRI, STAR*D Level 1 (n=2,876 general MDD)
Psychotherapy (CBT)
Meta-analysis of 409 RCTs, 52,702 patients (Cuijpers 2023)
2nd Medication Trial
Switch after 1st failure, STAR*D Level 2 (treatment-resistant)
3rd Medication Trial
After two prior failures, STAR*D Level 3
4th Medication Trial
After three prior failures, STAR*D Level 4
Standard rTMS (4–6 weeks)
Meta-analysis of 29 RCTs, HF-rTMS, treatment-resistant MDD (Berlim 2014)
AMPA ONE-D 1 Day
Open-label case series, n=32 TRD. Vaughn et al., TMS Journal 2025. At 6 weeks.
0%20%40%60%80%100%
Important context on comparability: These numbers span different study designs, patient populations, sample sizes, and outcome timepoints. STAR*D reflects general MDD; TMS rows reflect treatment-resistant MDD (≥1–2 prior medication failures). ONE-D (n=32) is a small unblinded open-label case series, not an RCT. This chart illustrates the landscape of options. It does not constitute a head-to-head efficacy claim.
STAR*D: Rush et al., Am J Psychiatry, 2006. Per-level response/remission on QIDS-SR (not cumulative).
CBT: Cuijpers et al., World Psychiatry, 2023. Meta-analysis, 409 RCTs, 52,702 patients.
rTMS: Berlim et al., Psychol Med, 2014. Meta-analysis, 29 RCTs, HF-rTMS, treatment-resistant MDD.
ONE-D: Vaughn et al., Transcranial Magnetic Stimulation, 2025. Open-label case series, n=32; assessed at 6 weeks.
D-cycloserine augmentation: Cole J, et al. JAMA Psychiatry, 2022;79(12):1153–1161. Double-blind RCT, n=50; iTBS + d-cycloserine vs iTBS + placebo. Response 73.9% vs 29.2%; remission 39.1% vs 4.2%.
Speed to Relief

Every square is one day
of waiting to feel better

High response rates matter, but so does when relief arrives. Each dot below represents one day of your life spent waiting for treatment to work. For people suffering from depression, that wait is not abstract.

Antidepressant Medication
SSRI/SNRI · 1st trial
84 days avg to remission
Waiting / taking daily Response (~wk 6) Remission (~wk 12)
Standard rTMS
5 days/wk · 4–6 weeks of clinic visits
30–36 clinic visits to complete
Clinic visit Weekend (no treatment) Response / remission (~wk 5–6)
AMPA ONE-D
20 iTBS sessions · single day
1 day · treatment complete
vs. medication: 83 fewer days
vs. standard rTMS: 35+ fewer clinic visits
Treatment complete. 1 day, 1 visit Source: Vaughn et al., 2025
84
days avg to remission
Antidepressant (STAR*D)
vs
36+
clinic visits required
Standard rTMS course
vs
1
day · 1 visit · done
AMPA ONE-D
Antidepressant: STAR*D: average ~6 weeks to response, ~7 weeks (84 days) to remission on Level 1 citalopram (NIMH; Rush et al., Am J Psychiatry, 2006). Standard rTMS: 5 days/week for 4–6 weeks per FDA-cleared protocol (Berlim et al., Psychol Med, 2014). ONE-D: single-day protocol, 20 sessions, treatment complete day-of-visit (Vaughn et al., TMS Journal, 2025). Dot grids show calendar days proportionally; rTMS weekends shown as dim squares. Treatment completion ≠ guaranteed sustained response for all patients.
Patients

Specialized care for
every situation

Adult Depression

For adults who have struggled with depression through medication trials, or who cannot commit to weeks of daily clinic visits, ONE-D offers a transformative alternative: a full treatment course, done in a single day.

  • Major Depressive Disorder (MDD)
  • Medication-resistant depression
  • Seeking non-medication alternatives
  • Cannot do multi-week daily visits
  • Travel patients (one trip, one day)
  • Depression with comorbid anxiety
Pediatric Depression

Dr. Hasassri provides age-adapted ONE-D care for adolescents. The single-day format means minimal school disruption and offers families a meaningful non-medication option during critical developmental years.

  • Adolescent MDD (typically ages 12+)
  • Treatment-resistant pediatric depression
  • Reducing medication burden
  • Only one day missed from school
  • Coordination with pediatric care teams
  • Full parent consultation & education
At-Home ONE-D

The AMPA Health TMS device is portable, allowing the complete ONE-D protocol to be delivered at your home, hotel, or another location of your choosing within the greater Bay Area. A travel fee applies, billed at Dr. Hasassri's hourly rate with a two-hour minimum, in addition to the standard program fee. Travel fees are confirmed prior to scheduling.

  • Full ONE-D treatment in your home
  • Maintenance & follow-up sessions
  • No clinic visit required
  • Available anywhere in the Bay Area
  • AMPA Health portable device
  • Travel fee applies · confirmed prior to scheduling
Is ONE-D Right for You?

Good candidates
for ONE-D

Dr. Hasassri conducts a comprehensive psychiatric evaluation to determine whether ONE-D is appropriate. Most good candidates share these characteristics:

Unipolar major depression . Bipolar disorder and psychotic features require separate evaluation
Inadequate response to at least one antidepressant , or preference for a non-medication approach
No metal implants in the head or neck . Pacemakers, cochlear implants, and ferromagnetic implants are contraindications to TMS
No personal history of seizures or epilepsy , a standard TMS safety requirement
Medically able to receive the augmentation medications . A full medication and health history review is required
Important safety considerations
The pharmacological augmentation medications used in ONE-D (d-cycloserine and lisdexamfetamine) are used off-label. They are contraindicated in certain conditions including stimulant hypersensitivity, certain cardiovascular conditions, and active substance use disorders. A complete medical and psychiatric evaluation is required before treatment. Dr. Hasassri will review all medications and your full history carefully before proceeding.
Your path to treatment
  • 1Free phone consultation: a brief call with Dr. Hasassri to discuss your history, answer your questions, and determine if ONE-D is a good fit. No commitment required
  • 2Medical clearance & preparation: labs, medication review, contraindication screening, and informed consent
  • 3ONE-D treatment day: arrive in the morning, complete all 20 sessions, depart the same evening
  • 4Follow-up monitoring: outcome check-ins at 1, 6, and 12 weeks; maintenance options available
Your Physician

Dr. Earth
Hasassri, MD

Dr. Earth Hasassri is a board-certified adult and child & adolescent psychiatrist based in Menlo Park, California, and Adjunct Clinical Assistant Professor of Psychiatry at Stanford University School of Medicine. His TMS background is not incidental to his practice; it is central to it.

Dr. Hasassri's TMS expertise was built across his UCSF psychiatry residency and Stanford fellowship, with clinical training at TMS Health Solutions and research experience in Stanford's Brain Stimulation Lab under Dr. Nolan Williams, one of the world's foremost TMS researchers. During his fellowship he contributed to TMS research in both adult and pediatric populations, including studies on safety and on novel applications in autism spectrum disorder, and has presented at Stanford Child Psychiatry Grand Rounds. He is a member of the Clinical TMS Society and holds certification through its clinical workshop program.

As a trained AMPA Health ONE-D provider, Dr. Hasassri is among a select group of physicians nationwide offering this protocol. His private practice model means every patient receives individualized, unhurried attention from the physician who knows their history, not a technician. For general psychiatric care outside of TMS, visit earthpsychiatry.com.

Board-Certified Psychiatrist Board-Certified Child & Adolescent Psychiatry AMPA Health ONE-D Provider TMS Research · Adult & Pediatric Clinical TMS Society Certified Adjunct Clinical Asst. Professor, Stanford Psychiatry
Education & Training
Fellowship, Child & Adolescent PsychiatryStanford University School of Medicine
Residency, PsychiatryUniversity of California, San Francisco · Clinical Neuroscience Area of Distinction
M.D.Mayo Clinic Alix School of Medicine
B.S. Physiology & Neuroscience · B.A. PsychologyUniversity of California, San Diego
Earth Hasassri, MD
Adult & Child Psychiatry · Neuromodulation · TMS
Adjunct Clinical Asst. Professor, Stanford Psychiatry
TMS ExpertiseClinical TMS Society certified · Stanford Brain Stimulation Lab · TMS research, adult & pediatric
Location648 Menlo Ave, Suite 1, Menlo Park, CA 94025  ·  General psychiatry practice
ProtocolAMPA Health ONE-D. Complete TMS course in a single day with neuroplasticity augmentation
PopulationsAdult & pediatric depression (adolescents typically 12+)
PaymentCash pay · No insurance billing
Travel patientsTelehealth intake and one in-person treatment day, accessible from anywhere
Investment

Transparent, cash-pay pricing

Cash Pay Only

Dr. Hasassri's practice operates on a private-pay basis. No prior authorization delays, no insurance denials, and no treatment decisions made by non-clinicians. Because ONE-D compresses an entire TMS course into a single day, the total investment is all-inclusive and transparent. Exact fees are discussed at your consultation.

Initial psychiatric consultation & evaluation
Medical clearance & contraindication screening
All 20 iTBS sessions on treatment day
Lunch, refreshments, and WiFi on treatment day
Pharmacological augmentation prescriptions
Motor threshold calibration
Full-day monitoring by Dr. Hasassri
Outcome assessments at 1, 6, 12 weeks
Pediatric family consultation (if applicable)
Post-treatment psychiatric follow-up
FAQ

Common questions

Traditional TMS requires patients to attend the clinic 5 days a week for 4–6 weeks, typically 20–36 separate visits. The AMPA Health ONE-D protocol delivers the equivalent of a full TMS course in a single day: 20 iTBS sessions spaced every 30 minutes across 9.5 hours, combined with neuroplasticity-priming medications taken before treatment. Published outcomes show response and remission rates substantially higher than conventional protocols, in a fraction of the time.
One hour before your first TMS session, you take a single oral dose of d-cycloserine and lisdexamfetamine. The rationale is grounded in neuroscience: iTBS works through synaptic plasticity, but depression impairs plasticity, which may limit how much TMS alone can achieve. D-cycloserine is an NMDA receptor partial agonist that addresses this directly. A 2022 double-blind, placebo-controlled RCT in JAMA Psychiatry (Cole et al., n=50) found response rates of 73.9% with iTBS plus d-cycloserine versus 29.2% with iTBS plus placebo, and remission rates of 39.1% versus 4.2%, with a large effect size (Hedges g = 0.99). Timing matters: the medication needs to be present in the brain during stimulation. Lisdexamfetamine augments dopamine and norepinephrine signaling to further support neuroplasticity. Both are used off-label and are physician-prescribed after a thorough safety evaluation.
Most patients describe iTBS as a rapid tapping or clicking sensation on the scalp. It is generally well-tolerated. Each session is only 3 minutes long. You remain fully awake throughout and can listen to music, browse, or rest between sessions in the waiting room, where WiFi and refreshments are provided. The most common side effects are mild scalp discomfort or a light headache, which typically resolve quickly. Serious adverse events are rare.
The foundational ONE-D paper (Vaughn et al., Transcranial Magnetic Stimulation, 2025) reported outcomes for 32 adults with medication-resistant unipolar depression. At 6 weeks: 87.5% response and 71.2% remission on HDRS-17; 90.6% response and 68.8% remission on BDI-II. At 26 weeks, 50% maintained remission. These are intention-to-treat results from an unblinded retrospective case series, not a randomized controlled trial, and should be interpreted with appropriate caution. They are nonetheless highly promising and consistent with the emerging accelerated TMS literature.
TMS has an excellent safety record in adults, and the FDA has now cleared several TMS devices specifically for use in adolescents with depression, including NeuroStar (2024) and BrainsWay (2025), for patients aged 15 and older. This regulatory recognition reflects the substantial real-world safety data accumulated in younger populations. The AMPA Health device used in ONE-D uses the same figure-8 coil design as these FDA-cleared pediatric systems. The specific ONE-D protocol itself has been studied primarily in adults, and adolescent application requires individualized clinical judgment. Dr. Hasassri performs a thorough evaluation of each adolescent patient, uses age-adapted parameters, and involves parents fully in the consent and treatment process.
Yes. Because ONE-D requires only a single treatment day (plus an initial evaluation, which can often be done via telehealth), it is particularly well-suited for travel patients. You would need a telehealth or in-person initial consultation, then one in-person treatment day in Menlo Park. Follow-up monitoring at weeks 1, 6, and 12 can typically be done via telehealth. Please contact us to discuss your situation.
Dr. Hasassri's practice is cash-pay only and does not bill insurance. Exact fees are discussed at your consultation.
Yes. The AMPA Health TMS device is portable, allowing the complete ONE-D protocol to be delivered at a patient's home, hotel, or other location of their choosing. Off-site treatment is available within the greater Bay Area. A travel fee applies for all off-site treatment days, calculated based on distance from the clinic at 648 Menlo Ave, Suite 1, Menlo Park to the treatment location and back. Travel fees are in addition to the standard program fee and are confirmed prior to scheduling. At-home ONE-D follows the same clinical protocol and physician supervision as in-office treatment.
Other Conditions & TMS Indications
Yes. TMS received FDA clearance for obsessive-compulsive disorder (OCD) in 2018, when the FDA authorized BrainsWay's Deep TMS system as an adjunct treatment for adult OCD patients. Multiple device manufacturers have since received their own FDA clearances for OCD, including NeuroStar and MagVenture. The FDA-cleared OCD protocol targets the anterior cingulate cortex and medial prefrontal cortex (ACC/mPFC) using deep TMS, and uniquely incorporates symptom provocation before each session to activate the relevant neural circuits. In the pivotal RCT (n=99), active deep TMS achieved a 38% response rate versus 11% for sham. TMS is indicated as an adjunct for OCD patients who have not had adequate response to medication and psychotherapy (ERP). Dr. Hasassri can evaluate whether TMS is appropriate for your OCD and discuss the available protocols.
TMS has FDA clearance for decreasing anxiety symptoms in adults with MDD who also have significant comorbid anxiety (anxious depression), with multiple devices cleared for this indication since 2021. This is distinct from a primary anxiety disorder diagnosis. For generalized anxiety disorder (GAD) as a standalone diagnosis, TMS does not currently have FDA clearance, though there is a growing body of research supporting its use and it is offered at many centers off-label. Multiple RCTs have found meaningful reductions in anxiety symptoms with rTMS targeting the left DLPFC and other circuits. Dr. Hasassri can discuss whether TMS is appropriate for your anxiety presentation, whether as an adjunct to depression treatment or as an off-label approach for primary anxiety.
TMS does not currently have FDA clearance specifically for PTSD, though it is one of the most actively studied off-label applications. Multiple RCTs have shown significant reductions in PTSD symptom severity with right-sided DLPFC inhibition and other targeting approaches. Beyond PTSD, FDA-cleared TMS indications include migraine headache (cleared since 2013 for the eNeura single-pulse device) and smoking cessation (BrainsWay Deep TMS, cleared 2020). Outside the US, TMS holds CE certification in Europe for a broader range of conditions including PTSD, bipolar disorder, Alzheimer's disease, Parkinson's disease, chronic pain, and the negative symptoms of schizophrenia. Research into accelerated protocols for many of these conditions is ongoing. Contact Dr. Hasassri to discuss whether TMS may be appropriate for your specific situation.
Get in Touch

Begin your
path to
recovery

Start with a free, brief phone consultation with Dr. Hasassri to explore whether ONE-D is right for you or your child. No commitment, no paperwork. Just a direct conversation with the physician. Dr. Hasassri's private practice model is designed to give you time, clarity, and genuine individualized care.

Location648 Menlo Ave, Suite 1, Menlo Park, CA 94025 · Serving the greater Bay Area
HoursMonday – Friday, 8:00 AM – 5:30 PM · Flexible intake scheduling
PaymentCash pay · No authorization delays
Travel patients welcomeTelehealth intake consult + one in-person treatment day

Select a time for a free phone consultation. All scheduling is handled through Dr. Hasassri's HIPAA-compliant patient portal.